Skip to main content
Erschienen in: Indian Journal of Hematology and Blood Transfusion 1/2016

01.03.2016 | Original Article

A Prospective Study of Adequacy of Anticoagulation with Fixed Dose Weight Adjusted Unfractionated Heparin in Patients with Deep Vein Thrombosis

verfasst von: Subash Chandra Bose, Rakhee Kar, Suryanarayana Bettadpura Shamanna

Erschienen in: Indian Journal of Hematology and Blood Transfusion | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Weight adjusted fixed dose subcutaneous unfractionated heparin (UFH) is one of the options for the treatment of deep vein thrombosis (DVT), but the degree of its anticoagulant effect has not been tested in India. This was a prospective observational study, conducted at a tertiary care hospital in South India between September 2012 and March 2014. DVT was diagnosed using compression ultrasonography. UFH was given as an initial loading dose of 333 U/kg followed by a maintenance dose of 250 U/kg twice daily subcutaneously. aPTT was done on day 2 and day 4 after 6 h of the morning dose of heparin. Patients were categorized based on aPTT ratios. Fifty five patients treated for proximal lower limb DVT had received UFH. Their median age was 41 years. DVT was secondary to malignancy, immobilisation or pro-coagulant state. No obvious etiology was found in 47 % of the patients. The mean aPTT on day 2 was 41.8 s and 51.7 s on day 4. The aPTT ratio was subtherapeutic in 63.6 % and therapeutic in 32.7 % of the patients on day 2. Five patients had adverse events in the hospital. Three patients died and two other patients had confirmed pulmonary embolism. Death was due to pulmonary embolism in one patient and metastatic malignancies in the other two. No bleeding manifestation had occurred. Caution is required in implementing this UFH regimen as this preliminary investigation has found predominantly subtherapeutic aPTT ratios during the initial phase of anticoagulation.
Literatur
1.
Zurück zum Zitat Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS (1998) Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 279:458–462CrossRefPubMed Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS (1998) Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 279:458–462CrossRefPubMed
2.
Zurück zum Zitat Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B et al (1991) A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 151:933–938CrossRefPubMed Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B et al (1991) A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 151:933–938CrossRefPubMed
3.
Zurück zum Zitat Lee LH, Gu KQ, Heng D (2002) Deep vein thrombosis is not rare in Asia–the Singapore General Hospital experience. Ann Acad Med Singap 31:761–764PubMed Lee LH, Gu KQ, Heng D (2002) Deep vein thrombosis is not rare in Asia–the Singapore General Hospital experience. Ann Acad Med Singap 31:761–764PubMed
4.
Zurück zum Zitat Cushman M (2013) Treating acute venous thromboembolism—shift with care. N Engl J Med 369:865–866CrossRefPubMed Cushman M (2013) Treating acute venous thromboembolism—shift with care. N Engl J Med 369:865–866CrossRefPubMed
5.
Zurück zum Zitat Goldhaber SZ, Bounameaux H (2012) Pulmonary embolism and deep vein thrombosis. Lancet 379:1835–1846CrossRefPubMed Goldhaber SZ, Bounameaux H (2012) Pulmonary embolism and deep vein thrombosis. Lancet 379:1835–1846CrossRefPubMed
6.
Zurück zum Zitat Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ et al (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e419S–e494SPubMedCentralCrossRefPubMed Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ et al (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e419S–e494SPubMedCentralCrossRefPubMed
7.
Zurück zum Zitat Kearon C, Ginsberg JS, Julian JA, Douketis J, Solymoss S, Ockelford P et al (2006) Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA 296:935–942CrossRefPubMed Kearon C, Ginsberg JS, Julian JA, Douketis J, Solymoss S, Ockelford P et al (2006) Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA 296:935–942CrossRefPubMed
8.
Zurück zum Zitat Kearon C, Harrison L, Crowther M, Ginsberg JS (2000) Optimal dosing of subcutaneous unfractionated heparin for the treatment of deep vein thrombosis. Thromb Res 97:395–403CrossRefPubMed Kearon C, Harrison L, Crowther M, Ginsberg JS (2000) Optimal dosing of subcutaneous unfractionated heparin for the treatment of deep vein thrombosis. Thromb Res 97:395–403CrossRefPubMed
9.
Zurück zum Zitat Munsamy JI, Kertland H, Parrish A (2010) Validation of a dosing regimen for fixed-dose, weight-adjusted, subcutaneous unfractionated heparin for the acute treatment of venous thrombo-embolism in a population from a resource-constrained environment. South Afr Med J 100:432–434 Munsamy JI, Kertland H, Parrish A (2010) Validation of a dosing regimen for fixed-dose, weight-adjusted, subcutaneous unfractionated heparin for the acute treatment of venous thrombo-embolism in a population from a resource-constrained environment. South Afr Med J 100:432–434
10.
Zurück zum Zitat Garcia DA, Baglin TP, Weitz JI, Samama MM (2012) Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e24S–e43SPubMedCentralCrossRefPubMed Garcia DA, Baglin TP, Weitz JI, Samama MM (2012) Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e24S–e43SPubMedCentralCrossRefPubMed
Metadaten
Titel
A Prospective Study of Adequacy of Anticoagulation with Fixed Dose Weight Adjusted Unfractionated Heparin in Patients with Deep Vein Thrombosis
verfasst von
Subash Chandra Bose
Rakhee Kar
Suryanarayana Bettadpura Shamanna
Publikationsdatum
01.03.2016
Verlag
Springer India
Erschienen in
Indian Journal of Hematology and Blood Transfusion / Ausgabe 1/2016
Print ISSN: 0971-4502
Elektronische ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-015-0563-9

Weitere Artikel der Ausgabe 1/2016

Indian Journal of Hematology and Blood Transfusion 1/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.